Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientheadto determinedetermine ifinjury
  Phrases that lowered it: the pharmacokineticsvolunteershealthyeffectpharmacokinetics of
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 3.3% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 30 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 34.6% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 2.6% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 45 (lowers risk) · Who can join
• Drug's FAERS reports before start: 191 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 60 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 24 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males NCT04470908 · started 2020 · scored riskier than 1% of active trials completed
• A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants NCT05577624 · started 2019 · scored riskier than 2% of active trials completed
• Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor NCT03259542 · started 2017 · scored riskier than 1% of active trials completed
• Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects NCT04843449 · started 2021 · scored riskier than 1% of active trials completed
• Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites NCT03258372 · started 2017 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.